(Circulation. 1995;91:794-801.)
© 1995 American Heart Association, Inc.
Articles |
From the Department of Internal Medicine, Veterans Administration Medical Center; and the University Heart Center, University of Arizona, Tucson, Ariz.
Correspondence to Dr Thomas E. Raya, Cardiology Section, 111C, Tucson Veterans Administration Medical Center, Tucson, AZ 85723.
| Abstract |
|---|
|
|
|---|
Methods and Results Male New Zealand White rabbits underwent
proximal circumflex coronary artery ligation. After infarction, rabbits
were treated with DITPA (3.75 mg/kg body wt) or placebo for 21 days and
then underwent conscious and open-chest hemodynamic studies. In
separate groups of rabbits, ß- and
-MHC isoforms were separated,
and relative proportions were measured using gradient sodium dodecyl
sulfatepolyacrylamide gel electrophoresis and laser densitometry.
Infarction resulted in increased left ventricular
end-diastolic pressure and prolonged left ventricular
relaxation (
) (P=.001 for both variables). Postinfarction
treatment with DITPA decreased left ventricular
end-diastolic pressure and
(P=.002 and
P=.001, respectively) and increased maximum positive and
negative dP/dt (P=.002 and P=.016,
respectively).
Infarcted rabbits treated with DITPA had no significant changes in
heart rate or left ventricular systolic pressure compared with
untreated rabbits with infarction. There were no significant
differences in heart rate, positive dP/dt, peak systolic pressure, or
between sham-operated rabbits and sham-operated rabbits treated
with DITPA. Although infarction resulted in increased left ventricular
diameter, there were no effects of DITPA on left ventricular
remodeling. Neither myocardial infarction nor treatment with DITPA
altered the ratio of MHC isoforms.
Conclusions Rabbits that survive occlusion of the circumflex artery will develop myocardial dysfunction and left ventricular remodeling. Therapy with DITPA, a thyroid hormone analogue, produces improvement in ventricular performance and reduces end-diastolic pressure. The hemodynamic effects of DITPA were not associated with alterations of MHC isoforms. Whether DITPA represents the prototype of a previously undescribed class of agents for the treatment of heart failure will need to be determined by clinical trials.
Key Words: 3,5-diiodothyropropionic acid heart failure thyroid ventricles
| Introduction |
|---|
|
|
|---|
,
)
to a predominantly V3(ß,ß) isoform.
MHC composition is upregulated from the V3 to the
V1 isoform by thyroid hormone, which binds to cardiac
nuclear receptors and alters gene expression via transcriptional
regulation.12 13 Earlier, we have shown that when
thyroid
hormone was administered to rats with heart failure after myocardial
infarction, left ventricular performance was improved, an effect that
was associated with upregulation of the V3 to the
V1 isoform.11 Recently, we showed that
3,5-diiodothyropropionic acid (DITPA), an analogue of thyroid hormone,
binds to the bacterially expressed thyroid hormone nuclear receptor
subtypes
1 and ß1 and induces
-MHC mRNA
expression in cultured cardiac myocytes.14 In hypothyroid
rats, it produces positive inotropic activity with minimal effects on
heart rate and metabolic activity.14 More recently, we
demonstrated that DITPA also improved cardiac performance when given,
in conjunction with captopril, to rats with heart
failure.15
Because rats differ from humans with respect to MHC isoenzyme composition, there also may be other important differences in proteins necessary for excitation-contraction coupling. Other investigators have shown that thyroid hormone alters other contractile proteins in addition to MHC.16 Using MHC composition as a biochemical marker, we hypothesized that an animal model with a V3(ß,ß) predominance would provide a more relevant model for studying human heart failure.
No model of cardiac dysfunction or remodeling after chronic coronary artery occlusion has been characterized in a predominantly V3 animal. We have recently developed a postinfarction model of left ventricular dysfunction in the rabbit, an animal in which V3 is the predominant MHC isoform. The purpose of this study was threefold: (1) to test the feasibility of using the V3 rabbit postinfarction model for the study of heart failure by characterizing the effects of chronic coronary artery occlusion on the left ventricle; (2) to determine whether monotherapy treatment with DITPA produces improvements in left ventricular function; and (3) to determine the effects of myocardial infarction and treatment with DITPA on MHC isoforms.
| Methods |
|---|
|
|
|---|
The experimental protocol consisted of four groups of rabbits: sham (thoracotomy, circumflex artery not ligated); sham-DITPA (sham, treated with thyroid hormone analogue); myocardial infarction (MI, thoracotomy, circumflex artery ligated); and MI-DITPA (thoracotomy, circumflex artery ligated, treated with thyroid hormone analogue). In alternating order, rabbits were preassigned to each group on the day of surgery.
Circumflex Artery Ligation
The method of circumflex artery
ligation was adapted from
previously described techniques.17 18 All surgical
procedures were performed in a sterile manner in the animal operating
suites at our facility. The rabbits were anesthetized in a halothane
inhalant chamber and an intramuscular injection of a ketamine (0.4 mg)
and acepromazine (20 mg) mixture was administered. Animals were
intubated and ventilated with a Harvard Rodent ventilator (model 683)
and monitored by continuous ECG tracing using standard limb leads.
Intravenous access was established.
The rabbits were placed on a warming blanket, and the chest was shaved and cleansed in sterile fashion. A left thoracotomy was performed through the fifth intercostal space, and the circumflex artery was exposed. A suture was placed around the artery at the origin of the vessel such that it could be loosened. For sham-operated animals, the suture was placed but removed at this time, and the chest was closed with layered sutures.
To prevent ventricular arrhythmias at the time of ligation of the circumflex artery, a series of repeated occlusions and reperfusions were done.17 First, a 2-minute occlusion was performed, and the extent of ischemia was visually and electrocardiographically assessed. After a 5-minute reperfusion period, the artery was again occluded, for 5 minutes, followed by 10 minutes of reperfusion. A third occlusion for 10 minutes was then performed, followed by 15 minutes of reperfusion. Finally, the artery was permanently ligated. Lidocaine (1 mg/kg IV) was administered during the final 15-minute reperfusion period or before closing the chest in sham-operated animals. If adequate ECG evidence for ischemia (ST-segment elevation of more than 3 mm in leads II, III, and aVF and/or I and aVL) was not appreciated, an additional ligature was applied to a branch of the circumflex or left anterior descending coronary artery using the same series of repeated occlusions and reperfusions. The chest was closed, and the rabbit was given a one-time subcutaneous dose of Bicillin (300 000 U) and was observed for several hours until stable.
In the event of sustained ventricular tachycardia or ventricular fibrillation during coronary occlusion or in the immediate postinfarction time period, the animals were given additional lidocaine (1 mg/kg IV). Cardioversion or defibrillation was performed as needed with 5 J of DC current using defibrillator paddles applied to the chest.
Fig 1
shows a photomicrograph of a typical
trichrome-stained thin section of the left ventricle from a
sham-operated and infarcted rabbit (Fig 1A
and
1B
, respectively). The
section was taken one third of the distance from the midpoint of the
ventricular anteroposterior axis toward the apex. The infarcted portion
is seen to lie along the posterolateral and apical portion of the left
ventricular wall.
|
Conscious Hemodynamics
Three weeks after surgery, conscious
hemodynamic measurements
were obtained. Rabbits were anesthetized with halothane in an inhalant
chamber, and a 5F micromanometer-tipped catheter (Millar Instruments)
was inserted into the left ventricle via the right carotid artery under
constant pressure monitoring. The zero-pressure baseline was obtained
by placing the pressure sensor in 37°C saline. The ventricular
catheter and a central venous catheter (PE 90) were inserted through
the right internal jugular vein and tunneled subcutaneously to the
dorsum of the animal. After a 4-hour recovery period in a rabbit cage,
heart rate, left ventricular systolic pressure, and left ventricular
end-diastolic pressure were recorded on a physiological
recorder (model 2400, Gould Instrument) and an IBM AT microcomputer in
which the high-frequency cutoff filter was set at 100 Hz. Left
ventricular pressure from 60 to 90 consecutive cardiac cycles was
digitized to ensure reproducibility; averaged data are reported. Heart
rate, rate of maximum positive and negative left ventricular pressure
development (dP/dt), and isovolumic relaxation time (
) were
determined using customized software as previously reported from our
laboratory.3 14 15
Open-Chest Determinations of Stressed Ventricular
Performance
The rabbit was anesthetized with intravenous
thiobutabarbital
(500 mg), intubated, and ventilated using mechanical ventilation. A
midsternotomy was performed. After left ventricular pressure and heart
rate stabilized, the ascending aorta was exposed, and a snare was
placed around the proximal vessel. While left ventricular systolic
pressure was being recorded, abrupt occlusion was produced by sudden
tightening of the snare. Peak developed pressure was defined as the
mean systolic pressure minus the mean end-diastolic
pressure over the first five stable beats after aortic
occlusion.1 15
To determine baseline and maximum flow-generating capacity of the heart,1 2 warmed (39°C) Tyrode's solution was infused (45 mL · min-1 · kg-1) while left ventricular end-diastolic pressure was recorded continuously. The infusion was continued for 90 to 120 seconds or until hemodynamic compromise was noted. Baseline open thorax end-diastolic pressure and postinfusion open-thorax end-diastolic pressure were recorded. Fifteen minutes after the volume infusion, when end-diastolic pressure had decreased to at least 75% of its postvolume peak, a precalibrated flow probe (3.0 mm id, Transonics Instruments) was placed around the ascending aorta, and the ventricular catheter was withdrawn into the right carotid artery so as not to interfere with flow-probe measurements. Baseline flow was then recorded (mL/min) as the integrated mean of pulsatile flow. Flow-generating capacity of the heart was then measured using warmed Tyrode's solution, infused as described above. Maximum flow-generating capacity was defined as the plateau of mean flow, which was usually achieved after 70 to 90 seconds of infusion.
Measurements of Ventricular Remodeling
Pressure-volume data
were recorded with methods described
previously.1 2 3 4 Briefly,
1000 U heparin was administered
intravenously followed by intravenous KCl (5 mL) to arrest the heart in
diastole. The heart was rapidly removed and rinsed in 0.9% NaCl, and
the right ventricle was incised. Two telescoped catheters (PE 10
inside/PE 90 outside for measurement of pressure and infusion of
saline, respectively) were inserted in the left ventricle via the
remnant aorta. The atrioventricular groove was identified, and a
ligature was passed around the heart and tied to isolate the left
atrium from the left ventricle. After gentle aspiration of the left
ventricle to remove excess blood and to reduce the pressure to -5
mm Hg, normal saline was infused at a rate of 3.3 mL/min into the
suspended left ventricle, and pressure was recorded continuously until
the pressure increased to 40 mm Hg. The accumulated fluid was
aspirated, and infusion was repeated. Three curves were obtained from
each ventricle within 15 minutes of cardiac arrest.
The heart was removed and resuspended, and the coronaries were perfused with 10% buffered formalin via the infusion catheter after it was withdrawn into the aortic remnant. The ventricles were separated from the atria, and the right ventricular free wall was dissected free from the septum. The ventricles were weighed individually and stored in 10% buffered formalin.
The length of the left ventricle was determined by inserting a probe through the aortic root and passing it to the apex. The probe was marked at the level of the aortic valve, removed, and measured using an electronic hand-held micrometer (10-2 mm sensitivity). The left ventricle was then transected at the midpoint. The major and minor diameters of the basilar portion were measured using the micrometer. The thickness of the noninfarcted left ventricular anterior wall was measured by averaging the micrometer-measured mural thickness at two sites approximately 30 degrees apart.
MHC Composition
An additional group of rabbits underwent
coronary ligation or
sham operation after randomization to treatment with DITPA or placebo
injection. Three weeks after surgery, the animals were anesthetized,
and left ventricular hemodynamics were measured according to the
previously described procedure. The animals were then killed with an
overdose of methoxyflurane, and the heart was removed. Left ventricles
were separated and weighed. The left ventricles were immediately frozen
in liquid nitrogen and placed in storage at -80°C until
MHC composition was analyzed.
Sodium dodecyl
sulfatepolyacrylamide gel electrophoresis (SDS-PAGE)
was performed as described by Esser et al.20 In brief,
left ventricular tissue was homogenized (1:10 wt/vol) in 62.5 mmol/L
Tris (pH 6.8). Protein concentrations were determined from an aliquot
of homogenate using the Peterson modification of the micro-Lowry
assay.19 Rabbit atrial and soleus tissue were prepared in
the same fashion for
- and ß-MHC controls, respectively. Vertical,
discontinuous SDS-PAGE was performed using a 4% to 9% linear gradient
resolving gel and a 3% stacking gel (total acrylamide concentrations,
respectively). Samples containing homogenate plus twofold concentration
Laemmli buffer (15 µL total volume, 1.25 to 10 µg total protein)
were electrophoresed with constant DC current starting at 25 mA/gel for
30 minutes and then increasing to 50 mA/gel for an additional 3
hours.
After electrophoresis, gels were placed in 10% (wt/vol)
trichloroacetic acid for 15 minutes to limit protein diffusion and then
stained with Coomassie blue overnight. The Coomassie blue solution
consisted of equal volumes of solution A (0.3% [wt/vol] Coomassie
blue R-250, 90% [vol/vol] ethanol) and solution B (1%
[wt/vol]
copper sulfate in 20% [vol/vol] glacial acetic acid). Gels were
destained for 3 to 5 hours in a solution of 0.5% (wt/vol) copper
sulfate, 10% (vol/vol) glacial acetic acid, and 25% (vol/vol)
methanol. Gels were subsequently scanned on a laser densitometer (LKB
UltraScan XL 2222-020). Relative areas under the
- and ß-MHC peaks
were calculated using system software that accompanied the
densitometer.
Calculations
According to previously described
methods,1 2 3 4 the
measured pressure (P)-volume (V) data were fitted to an exponential
equation P=P0eKV, where K,
the chamber stiffness constant, was derived from a plot of
lnP=KV+lnP0. Left ventricular end-diastolic
volume index was defined as the infused ex vivo left ventricular volume
measured at pressure equal to in vivo end-diastolic
pressure. Left ventricular chamber volume (V) was defined as
ventricular cavity volume at a distending pressure of 10 mm Hg, as
determined from the pressure-volume relation. Left ventricular wall
volume, VW, was determined from the mass of the left
ventricle, such that VW is left ventricular mass (g)/1.06
(density of muscle). The ratio of V to VW was then
calculated as a measure of relative ventricular dilatation and
hypertrophy.
Infarct Sizing
After the morphometric measurements were
taken, the left
ventricle was cut from apex to base in three transverse slices and
embedded in paraffin. Thin sections of the left ventricle were stained
with Masson's trichrome. The three sections were projected using an
overhead projector and traced on 8
x11-in
sheets of paper.
The circumferences of the infarcted and noninfarcted segments of the
epicardial and endocardial surfaces were measured by digitization using
an IBM AT compatible personal computer equipped with customized
software. Infarct size is reported as the mean percent of the
endocardial and epicardial circumferences involved with scar tissue for
the three sections.1 2 3 4
DITPA
For experiments, stock solutions of DITPA (Sigma
Chemical Co)
were prepared by dissolving the powder in concentrated sodium hydroxide
and diluting to 20 mg/mL with distilled water.14 15
Hydrochloric acid was used to adjust the pH to 7 to 8. Animals were
treated with a daily subcutaneous injection of DITPA, 3.75 mg/kg body
wt, or an equivalent volume of 0.9% saline for 21 days. Treatment was
started on the first postoperative day and continued to the morning of
study.
Statistical Analysis
Values are given as mean±SD. To
evaluate whether there was an
interaction between DITPA treatment and infarction, all data were
analyzed by a two-factor ANOVA. The analysis tested the main
effects (DITPA, yes/no; infarction, yes/no) and an interaction between
DITPA and infarction. We also analyzed sham versus sham-DITPA, and
infarction versus infarction-DITPA, using separate unpaired
t tests. Significance was defined at the P<.05
level.
| Results |
|---|
|
|
|---|
There were no significant differences in final body weights (kg) among
the four groups of rabbits: 3.89±0.43, 3.78±0.41,
3.76±0.16, and
3.64±0.19, for sham, infarct, sham-DITPA, and infarct-DITPA,
respectively. Percent weight gain, from time of surgery to day of
study, also was similar among the four groups: 4.6±6.4%,
5.8±7.1%,
5.8±4.3%, and 3.2±7.5%. Mean infarct size was similar between
untreated and DITPA-treated rabbits (24±6% versus 24±7%; range,
15% to 33% and 17% to 35%, respectively). Conscious left
ventricular hemodynamics in the four groups of rabbits are shown in
Table 1
. With respect to the main effects of infarction,
left ventricular end-diastolic pressure and left
ventricular relaxation (
) were increased (P=.001 for both
variables) after coronary artery ligation. The main effects of DITPA
treatment were to decrease left ventricular end-diastolic
pressure and
(P=.002 and P=.001,
respectively) and to increase maximum positive and negative dP/dt
(P=.002 and P=.016, respectively). There were
no
differences in heart rate, positive dP/dt, peak systolic pressure, or
between sham-operated rabbits and sham-operated rabbits treated
with DITPA. Peak negative dP/dt, however, was significantly increased
in the sham-treated rabbits. Infarcted rabbits treated with DITPA had
no changes in heart rate or systolic pressure compared with untreated
rabbits with infarction. However, compared with untreated rabbits with
infarction, left ventricular end-diastolic pressure and
relaxation time (
) were reduced 54% and 29%, respectively, toward
normal (P=.005 for both variables) by DITPA treatment.
Compared with untreated infarcted rabbits, maximum positive and
negative dP/dt were increased (P=.005 and
P=.001,
respectively) in DITPA-treated rabbits with infarction. There was a
significant interaction between infarction and DITPA treatment for left
ventricular end-diastolic pressure and
, indicating that
in the presence of infarction, DITPA treatment had specific effects on
these variables.
|
Open-chest measurements of left ventricular performance are shown in
Table 2
. With respect to the main effects of infarction,
rabbits with infarction had decreased (P=.042) maximum flow
generating capacity (cardiac index stress) and elevated
end-diastolic pressure at peak flow (P=.002).
Treatment with DITPA had no effects on any baseline or stress variable,
although there was a trend for peak developed pressure and peak flow to
be increased in treated rabbits. In sham-operated rabbits, there was no
effect of DITPA treatment on peak developed pressure, cardiac index at
rest or with stress, or baseline end-diastolic pressure or
end-diastolic pressure at peak flow. When infarcted rabbits
treated with DITPA were compared with untreated infarcted rabbits,
there was an improvement in peak developed pressure and cardiac index
stress in treated animals (P=.017 and P=.005,
respectively). Data from resting and stress cardiac index, in the form
of cardiac function curves, are displayed in Fig 2
.
Treatment of infarcted rabbits with DITPA shifted the depressed curve
in untreated controls upward and to the left. There were no significant
interactions between infarction and treatment on any variable of stress
cardiac function.
|
|
Derived indexes of left ventricular remodeling are shown in Table
3
. There was a trend toward increased left ventricular
end-diastolic volume index (P=.051) after
infarction. There were no effects, however, of either infarction or
treatment on the chamber stiffness constant (Kc) or the
ratio of left ventricular cavity volume (at pressure of 10 mm Hg) to
left ventricular wall volume (V/Vw). There were no
interactions between infarction and treatment on remodeling parameters,
nor were there any significant differences between untreated animals
and respective treated controls.
|
Measured indexes of cardiac remodeling are displayed in Table
4
. Left ventricular diameter was increased
(P=.002) after infarction, whereas treated animals showed a
trend toward increased left ventricular length. Neither infarction nor
treatment produced any differences in heart weights or in left
ventricular wall thickness. There were no differences between untreated
animals and their respective treated controls in any measured index of
left ventricular remodeling.
|
MHC Composition
In rabbits assigned to the protocol for assay
of MHC composition,
unconscious left ventricular hemodynamics were obtained before they
were killed and ventricular tissue was obtained. A total of 17 rabbits
were studied: sham (n=4), sham-DITPA (n=4), infarct
(n=5), and
infarct-DITPA (n=4). There were no significant differences in heart
rate between the four groups. Left ventricular systolic pressure and
positive dP/dt were decreased and left ventricular
end-diastolic pressure and
were increased in the
untreated infarct rabbits compared with sham, sham-DITPA, and MI-DITPA
groups (P<.05 for all comparisons).
The percentage of
-MHC for the four groups was as follows:
39.5±1.3%, 43.3±1.5%, 41.4±7.5%, and 44.7±6.2% for
sham,
sham-DITPA, MI, and MI-DITPA, respectively. The percentage of ß-MHC
for the four groups was as follows: 60.5±1.3%, 56.7±1.5%,
58.6±7.5%, and 55.3±6.2% for sham, sham-DITPA, MI, and MI-DITPA,
respectively. There were no significant differences in the proportion
of either myosin isoform among the four groups.
| Discussion |
|---|
|
|
|---|
Long-term Effects of Myocardial Infarction in Rabbits
Using
techniques similar to those reported earlier for measurement
of infarct size,20 we confirmed that rabbits that survive
for longer than 1 week after coronary occlusion generally have
myocardial infarctions less than 30% in magnitude. In our study, there
were only 4 rabbits with infarct sizes of more than 30%-two in the
DITPA-treated group and two in the untreated group. The infarct size
that is compatible with early survival and heart failure in rabbits is
similar to the amount of damage reported in humans as causing
compromised left ventricular function.21 By contrast, in
the rat model, infarction sizes of more than 40% are routinely
observed in animals that survive weeks or
months1 2 3 4 7
until the time of experimental studies. The differences between infarct
size in rat and rabbits undergoing coronary ligation are not clear but
may be related to differences in coronary anatomy or postinfarction
collateral development. The proximal level at which the artery is
ligated, or the technique of ischemic preconditioning versus abrupt
occlusion, may also be contributory.
Although we do not specifically report the relation of ST-segment shifts at the time of coronary occlusion to chronic infarct size, we observed that the amount of myocardial damage, as histologically assessed in the postinfarct period, bore little relation to either the extent of contiguous ECG abnormalities or the magnitude of acutely measured ST-segment elevation. Thus, unlike the rat postinfarction model, in which ECG screening can be highly specific for large infarction,1 2 3 4 7 alternative ECG or perhaps imaging techniques will need to be developed that can predict infarct size before death in the rabbit.
The present study also demonstrates the feasibility of obtaining extensive conscious hemodynamic measurements in rabbits with small or moderately large myocardial infarctions. The data from these hemodynamic studies show that rabbits with infarct sizes that average 26% develop marked elevations in left ventricular end-diastolic pressure, decreased rate of pressure development, and abnormal prolongation of isovolumic ventricular relaxation. Ventricular performance measured under conditions of maximum preload and afterload stress is also impaired, as manifested by a decrease in maximum left ventricular pressure development and flow generation. These results are similar to those seen in the rat infarct model.1 2
It is generally agreed that ventricular remodeling represents a cardiac response to chronic alterations in ventricular loading.22 In the present study, rabbits with myocardial infarction had significant increases in left ventricular midcavity diameter and a trend toward increases in left ventricular length and end-diastolic volume index. However, left ventricular wall thickness, measured in the noninfarcted anterior wall, was not decreased. The effect of these alterations in left ventricular geometry was to maintain a normal cavity volumetowall volume ratio (V/VW).
In summary, it is apparent that alterations in left ventricular systolic and diastolic function are present despite a modest but significant increase in left ventricular diameter and a trend toward increased end-diastolic volume. These data further suggest that although the size of myocardial infarction was large enough to promote cavity dilatation, compensatory ventricular hypertrophy occurred that was sufficient to maintain V/VW constant.
Effects of Thyroid Hormone Analogue DITPA
We earlier
demonstrated in the rat postinfarction model that
treatment with DITPA, when combined with captopril, increased cardiac
index and -dP/dtmax and decreased left ventricular
end-diastolic pressure and
.15 In that
study, DITPA was added to captopril because converting-enzyme
inhibitors are the mainstay of treatment for heart failure. In the
present study, which was designed to examine the effects of
monotherapy, DITPA treatment alone produced significant improvement in
resting and stress left ventricular hemodynamics in infarcted rabbits.
The effects of infarction and treatment on resting and stress cardiac
index have been summarized graphically in Fig 2
. It can be
readily
observed that the effects of DITPA are to shift the Frank-Starling
relation of infarcted rabbits upward and to the left. These results are
in contrast to those in infarcted rats treated with captopril alone, in
which end-diastolic pressure and remodeling are decreased
even though relaxation and global systolic indexes of resting and
stress ventricular function are not improved.15
As in the rat model, the direct myocardial effects of DITPA are likely to be a major underlying reason for the improvement seen in cardiac performance in infarcted rabbits. First, heart rate was not significantly different between untreated and treated infarcted rabbits. Second, because left ventricular end-diastolic pressure was lower in treated rabbits and since both groups of infarcted rabbits had similar remodeling characteristics and volume stiffness, increased preload was probably not the reason for improvement in cardiac performance in DITPA-treated rabbits. Evidence supporting the contention that afterload was not decreased in DITPA-treated infarcted rabbits is that similar left ventricular systolic pressures at rest were observed between the two postinfarction groups, which was not associated with a change in resting cardiac index.
The effect of DITPA on left ventricular performance is most likely due to upregulation of thyroid hormone-responsive genes. However, the results of the gradient SDS-PAGE of cardiac MHCs suggest that the hemodynamic improvement of rabbits with left ventricular dysfunction after myocardial infarction does not depend on upregulation of ß-MHC. Although this result was somewhat surprising, it was not wholly unexpected. First, the presence of left ventricular dysfunction in the untreated infarcted group did not appear to depend on further downregulation of V3, since percent ß-MHC was not significantly altered in any group. Second, although we have shown that rats downregulate to V3 after large myocardial infarction and severe left ventricular dysfunction occurs,11 these results do not necessarily indicate a cause-and-effect relation. These results also should not be extrapolated to the rabbit model. Third, it is unclear whether improvement of left ventricular function in rats with ischemic heart failure treated with thyroxine11 or DITPA15 is directly related to upregulation of V3. For example, previous investigators have shown that preservation of normal myosin ATPase activity and myosin isoform distribution in infarcted rats was not associated with any apparent improvement in cardiac performance.23 An alternative explanation for the improvement in ischemic left ventricular dysfunction in both rats and rabbits after treatment with DITPA is the upregulation of other thyroid hormoneresponsive genes, for example, the sarcoplasmic reticulum calcium ATPase and the ryanodine-sensitive release channel.16 24 25 Since it is known that calcium handling is altered in heart failure,6 26 it is plausible that treatment with DITPA reverses abnormalities of calcium handling. The interaction between DITPA treatment and infarction in this study suggests the reversal of a process specific to heart failure.
Thyroid hormone, as long-term treatment for heart failure after myocardial infarction in rats, does not decrease left ventricular end-diastolic pressure at doses that improve left ventricular performance.11 In the present study, DITPA decreased left ventricular end-diastolic pressure while improving ventricular performance. The reasons for the differential effects of the native hormone versus the analogue are not clear. One potential explanation is that thyroxine, at doses necessary for effects on systolic function, produces greater increases in blood volume and venoconstriction than DITPA.27 The combined effect of these changes in the peripheral circulation has been shown to be associated with an increase in left ventricular end-diastolic pressure and volume in rats after myocardial infarction.4 An alternative reason for the decrease in left ventricular filling pressure in infarcted rabbits after DITPA treatment may be related to the marked improvement in ventricular relaxation that was associated with treatment. However, we know of no previous investigations that have examined the independent effects of changes in left ventricular relaxation on ventricular filling pressure, and thus the plausibility of this explanation will need to be established by further studies.
Treatment with DITPA produced no discernible effects on heart weights or on any variable of left ventricular remodeling in either sham-operated or infarcted rabbits. These results are similar to those obtained in our earlier study in rats with large infarctions, where treatment with DITPA and captopril had minimal effects on left ventricular remodeling.15 Earlier studies of infarcted rats treated with captopril have demonstrated attenuation of left ventricular remodeling only in the presence of moderate-sized infarcts.28 It is possible, therefore, that the addition of captopril to DITPA in rabbits with moderate-sized infarctions may have further improved left ventricular performance.
Study Limitations
Other potential mechanisms that might
explain the action of DITPA
were not explored in the present study. Future investigations
should include evaluation of the relation between the physiological
effects of thyroid hormone analogues such as DITPA and the biochemical
and molecular pathways that influence calcium handling in the failing
heart.
Although it has been shown in rats after infarction that V/VW is proportional to infarct size,2 we did not obtain sufficient numbers of infarcted rabbits with large (>30%) myocardial infarctions to test the hypothesis that wall thinning in the noninfarcted myocardium is also a function of infarct size in rabbits.
An example of the problems associated with anesthesia can be
seen in
comparing data in Tables 1
and 2
. The resting
left ventricular
end-diastolic pressure in the conscious infarcted animals
is decreased with DITPA treatment (Table 1
), whereas with the
open
chest measurements, there is only a trend for the
end-diastolic pressure to be lowered by DITPA (Table 2
). In
this report, we have stressed the conscious hemodynamics because of the
well known limitations of obtaining data during surgery and
anesthesia.
Summary and Implications
Rabbits that survive occlusion of
the circumflex artery
develop myocardial dysfunction and left ventricular remodeling. Along
with a previous investigation in which alterations in neurohormones and
baroreflex responses were described,20 the present
study establishes the rabbit as an alternative model of chronic left
ventricular dysfunction. Treatment with the thyroid hormone analogue
DITPA produces improvement in ventricular performance and reduces
end-diastolic pressure. Whether DITPA represents
the prototype of a previously undescribed class of
agents29 that will be efficacious for the treatment of
heart failure will need to be verified by clinical trials.
| Acknowledgments |
|---|
Received August 2, 1994; accepted August 31, 1994.
| References |
|---|
|
|
|---|
2.
Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left
ventricular diastolic pressure-volume relations in rats with healed
myocardial infarction: effects on systolic function.
Circ Res. 1981;49:618-626.
3.
Raya TE, Gay RG, Lancaster L, Aguirre M, Moffett C,
Goldman S. Serial changes in left ventricular relaxation and chamber
stiffness after large myocardial infarction in rats.
Circulation. 1988;77:1424-1431.
4.
Raya TE, Gay RG, Aguirre M, Goldman S. Importance of
venodilatation in prevention of left ventricular dilatation after
chronic large myocardial infarction in rats: a comparison of captopril
and hydralazine. Circ Res. 1989;64:330-337.
5.
Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda K,
Johnston CI. Neurohumoral responses to chronic myocardial infarction in
rats. Circulation. 1988;78:376-381.
6.
Afzal N, Dhalla N. Differential changes in left and right
ventricular SR calcium transport in congestive heart failure. Am
J Physiol. 1992;262:H868-H874.
7.
Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after
an experimental myocardial infarction: beneficial effects of long-term
therapy with captopril. Circulation. 1985;72:406-412.
8. Pfeffer MA, Braunwald EB, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction. N Engl J Med. 1992;327:669-677. [Abstract]
9. Mercadier JJ, Lompre AM, Duc P, Boheler KR, Fraysse JB, Wisnewsky C, Allen PD, Komajada M, Schwartz K. Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305-309.
10. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310. [Abstract]
11.
Gay RG, Graham S, Aquirre M, Goldman S, Morkin E. Effects of
10-12 days treatment with L-thyroxine in rats with myocardial
infarction. Am J Physiol. 1988;255:H801-H806.
12. Dillmann W. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88:626-630. [Medline] [Order article via Infotrieve]
13.
Evans R. The steroid and thyroid hormone receptor superfamily.
Science (Wash DC). 1988;240:889-895.
14.
Pennock GD, Raya TE, Bahl JJ, Goldman S, Morkin E. Cardiac
effects of 3,5-diiodothyropropionic acid, a thyroid analogue with
inotropic selectivity. J Pharmacol Exp Ther. 1992;263:163-169.
15.
Pennock GD, Raya TE, Bahl JJ, Goldman S, Morkin E. Combination
treatment with captopril and the thyroid hormone analogue
3,5-diiodothyropropionic acid (DITPA): a new approach to improving left
ventricular performance in heart failure.
Circulation. 1993;88:1289-1298.
16.
Arai M, Otsu K, MacLennan DH, Alpert NR, Periasamy M. Effect
of thyroid hormone on the expression of mRNA encoding sarcoplasmic
reticulum proteins. Circ Res. 1991;69:266-276.
17. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol. 1987;253: H1470-H1476.
18. Hof RP, Takiguchi Y, Nussberger J, Hof A, Klay M, Peters T, Zelis R, Brunner HR. Baroreflex and atrial natriuretic factor concentration correlate with myocardial infarct size and predict early death in rabbits: implications for drug studies. J Cardiovasc Pharm. 1991;18:361-368. [Medline] [Order article via Infotrieve]
19. Peterson GL. A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem. 1977;83:346-356. [Medline] [Order article via Infotrieve]
20.
Esser KA, Boluyt MO, White TP. Separation of cardiac
myosin heavy chains by gradient SDS-PAGE. Am J
Physiol. 1988;255:H659-H663.
21.
Klein MD, Herman MW, Gorlin RG. A hemodynamic study of left
ventricular aneurysm. Circulation. 1967;35:614-630.
22.
Pfeffer MA, Braunwald E. Ventricular remodeling after
myocardial infarction: experimental observations and clinical
implications. Circulation. 1990;81:1161-1172.
23.
Buttrick P, Perla C, Malhotra A, Geenen D, Lahorra M, Scheuer
J. Effects of chronic dobutamine on cardiac mechanics and bio-chemistry
after myocardial infarction in rats. Am J Physiol. 1991;260:H473-H479.
24.
Nagai R, Zarain-Herzberg A, Brandl CJ, Fujii J, Tada M,
MacLennan DH, Alpert NR, Perisamy M. Regulation of myocardial
Ca2+-ATPase and phospholamban mRNA expression in
response to pressure overload and thyroid hormone. Proc Natl Acad
Sci U S A. 1989;86:2966-2970.
25.
Rohrer D, Dillmann W. Thyroid hormone markedly increases the
mRNA coding for sarcoplasmic reticulum Ca2+-ATPase
in the rat heart. J Biol Chem. 1988;263:6941-6944.
26. Takahashi T, Allen PD, Marks AR, Denniss AR, Schoen FJ, Grossman W, Marsh JD, Izumo S. Altered expression of genes encoding the Ca2+ regulatory proteins in the myocardium of patients with end-stage heart failure: correlation with expression of the Ca2+-ATPase gene. Circ Res. 1992;71:1357-1365.
27.
Gay RG, Raya TE, Lancaster LD, Lee RW, Morkin E, Goldman
S. Effects of thyroid state on venous compliance and left ventricular
performance in rats. Am J Physiol. 1988;254:H81-H89.
28.
Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic
captopril therapy on the infarcted left ventricle of the rat.
Circ Res. 1985;57:84-95.
29. Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol. 1993;22:1223-1227.[Abstract]
This article has been cited by other articles:
![]() |
S. Goldman, M. McCarren, E. Morkin, P. W. Ladenson, R. Edson, S. Warren, J. Ohm, H. Thai, L. Churby, J. Barnhill, et al. DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study Circulation, June 23, 2009; 119(24): 3093 - 3100. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, D. Wang, R. A. Redetzke, B. A. Sherer, and A. M. Gerdes Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1551 - H1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vargas, J. M. Moreno, I. Rodriguez-Gomez, R. Wangensteen, A. Osuna, M. Alvarez-Guerra, and J. Garcia-Estan Vascular and renal function in experimental thyroid disorders Eur. J. Endocrinol., February 1, 2006; 154(2): 197 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kenessey and K. Ojamaa Ligand-mediated decrease of thyroid hormone receptor-{alpha}1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H813 - H821. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Adamson, N. Maitra, J. Bahl, K. Greer, S. Klewer, J. Hoying, and E. Morkin Regulation of Gene Expression in Cardiomyocytes by Thyroid Hormone and Thyroid Hormone Analogs 3,5-Diiodothyropropionic Acid and CGS 23425 [N-[3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic Acid] J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 164 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zheng, R. M. Weiss, X. Wang, R. Zhou, A. M. Arlen, L. Lei, E. Lazartigues, and R. J. Tomanek DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1994 - H2000. [Abstract] [Full Text] [PDF] |
||||
![]() |
F R Quinn, S Currie, A M Duncan, S Miller, R Sayeed, S M Cobbe, and G L Smith Myocardial infarction causes increased expression but decreased activity of the myocardial Na+--Ca2+ exchanger in the rabbit J. Physiol., November 15, 2003; 553(1): 229 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Nusz, D. C. White, Q. Dai, A. M. Pippen, M. A. Thompson, G. B. Walton, C. J. Parsa, W. J. Koch, and B. H. Annex Vascular rarefaction in peripheral skeletal muscle after experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1554 - H1562. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, W. Zheng, L. P. Christensen, and R. J. Tomanek DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H613 - H618. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Friberg, S. Werner, G. Eggertsen, and S. Ahnve Rapid Down-regulation of Thyroid Hormones in Acute Myocardial Infarction: Is It Cardioprotective in Patients With Angina? Arch Intern Med, June 24, 2002; 162(12): 1388 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Preckel, W. Schlack, T. Heibel, and H. Rutten Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function Br. J. Anaesth., February 1, 2002; 88(2): 264 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ojamaa, A. Kenessey, R. Shenoy, and I. Klein Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1319 - E1324. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. U. Trost, E. Swanson, B. Gloss, D. B. Wang-Iverson, H. Zhang, T. Volodarsky, G. J. Grover, J. D. Baxter, G. Chiellini, T. S. Scanlan, et al. The Thyroid Hormone Receptor-{beta}-Selective Agonist GC-1 Differentially Affects Plasma Lipids and Cardiac Activity Endocrinology, September 1, 2000; 141(9): 3057 - 3064. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Wickenden, R. Kaprielian, X.-M. You, and P. H. Backx The thyroid hormone analog DITPA restores Ito in rats after myocardial infarction Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1105 - H1116. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Litwin, D. Zhang, P. Roberge, and G. D. Pennock DITPA prevents the blunted contraction-frequency relationship in myocytes from infarcted hearts Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H862 - H870. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.A. McIntosh, S.M. Cobbe, and G.L. Smith Heterogeneous changes in action potential and intracellular Ca2+ in left ventricular myocyte sub-types from rabbits with heart failure Cardiovasc Res, January 14, 2000; 45(2): 397 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Maurice, A. S. Shah, A. P. Kypson, J. A. Hata, D. C. White, D. D. Glower, and W. J. Koch Molecular beta -adrenergic signaling abnormalities in failing rabbit hearts after infarction Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1853 - H1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Z. Atkins, C. W. Lewis, W. E. Kraus, K. A. Hutcheson, D. D. Glower, and D. A. Taylor Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ Ann. Thorac. Surg., January 1, 1999; 67(1): 124 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Skolnick, S. E. Litwin, W. H. Barry, and K. W. Spitzer Effect of ANG II on pHi, [Ca2+]i, and contraction in rabbit ventricular myocytes from infarcted hearts Am J Physiol Heart Circ Physiol, November 1, 1998; 275(5): H1788 - H1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Lewis, B. Z. Atkins, K. A. Hutcheson, C. T. Gillen, M. C. Reedy, D. D. Glower, and D. A. Taylor A load-independent in vivo model for evaluating therapeutic interventions in injured myocardium Am J Physiol Heart Circ Physiol, November 1, 1998; 275(5): H1834 - H1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Litwin and J. H. B. Bridge Enhanced Na+-Ca2+ Exchange in the Infarcted Heart : Implications for Excitation-Contraction Coupling Circ. Res., December 19, 1997; 81(6): 1083 - 1093. [Abstract] [Full Text] |
||||
![]() |
G. D. Pennock, D. D. Yun, P. G. Agarwal, P. H. Spooner, and S. Goldman Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H2018 - H2029. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Wildhirt, H. Suzuki, D. Horstman, S. Weismuller, R. R. Dudek, K. Akiyama, and B. Reichart Selective Modulation of Inducible Nitric Oxide Synthase Isozyme in Myocardial Infarction Circulation, September 2, 1997; 96(5): 1616 - 1623. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |